Novartis Bags Another Bolt-On With Cadent Buy
Pays $210m Upfront For Cognitive Disorder Biotech
Having worked with the Cambridge, MA-based neurology specialist for five years on a treatment-resistant depression drug, Novartis has decided to buy all of Cadent in a deal that could be worth up to $770m.
You may also be interested in...
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
The Swiss major is paying up to $280m to buy Vedere Bio, which has developed photoreceptor-protein based optogenetic therapies that are delivered to the retina intravitreally to restore vision.
News that the UK government will not procur any doses of AstraZeneca’s Evusheld for the prevention of COVID-19 infections in immunocompromised people has been greeted with dismay and the move will hurt the combo's already-limited sales growth.